.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Women's Health Initiative clarified that menopausal hormone therapy has both benefits and risks that depend on age, timing, formulation and patient characteristics. Estrogen plus progestin effectively reduces vasomotor symptoms and protects against fractures, but long-term randomized trial data showed increased risks of breast cancer and thromboembolic events in the studied population. Subsequent analyses have reinforced the importance of starting treatment near menopause when appropriate and using the lowest effective dose for the shortest duration consistent with treatment goals, while recognizing that individual risk varies. For gynecologists, the practical task is shared decision-making. Women with severe symptoms may derive substantial quality-of-life benefit, but cardiovascular, thrombotic, breast-cancer and uterine risks must be assessed. Nonhormonal treatments and local vaginal estrogen may be appropriate alternatives for specific symptom profiles.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The Women's Health Initiative clarified that menopausal hormone therapy has both benefits and risks that depend on age, timing, formulation and patient characteristics. Estrogen plus progestin effectively reduces vasomotor symptoms and protects against fractures, but long-term randomized trial data showed increased risks of breast cancer and thromboembolic events in the studied population. Subsequent analyses have reinforced the importance of starting treatment near menopause when appropriate and using the lowest effective dose for the shortest duration consistent with treatment goals, while recognizing that individual risk varies. For gynecologists, the practical task is shared decision-making. Women with severe symptoms may derive substantial quality-of-life benefit, but cardiovascular, thrombotic, breast-cancer and uterine risks must be assessed. Nonhormonal treatments and local vaginal estrogen may be appropriate alternatives for specific symptom profiles.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
